ProfileGDS5678 / 1426260_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 94% 94% 91% 95% 93% 93% 94% 93% 94% 93% 92% 92% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.0685894
GSM967853U87-EV human glioblastoma xenograft - Control 28.0790594
GSM967854U87-EV human glioblastoma xenograft - Control 38.1566594
GSM967855U87-EV human glioblastoma xenograft - Control 47.5037591
GSM967856U87-EV human glioblastoma xenograft - Control 58.5683495
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.6348293
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.6961693
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.1782394
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.9416593
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.0663494
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.790193
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.7762392
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.7046292
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.958293